# REDTEAM_R4_EDITOR.md
# Role: Handling Editor, Critical Care Medicine
# Task: Final accept/reject-framing call + abstract that survives review
# Date: 2026-06-30
# Based on: ICU_OCCULT_DEPENDENCE.md, REDTEAM_R3_SYNTHESIS.md, REDTEAM_R3_NOVELTY.md

---

## 1. THE IRREDUCIBLE CONTRIBUTION (one sentence)

Among ICU patients whose MAP is at target — the population the monitor already classifies as hemodynamically managed — the vasopressor requirement stratifies post-24h mortality across a 9-fold gradient (3.1% to 27.8%) with an AUC of 0.74 that the MAP value itself cannot approach (AUC 0.47, widening the requirement-vs-MAP information gap from 0.156 outside the target band to 0.268 within it), a risk-stratification finding that is distinct from VIS, VDI, and BPRI because none of those constructs condition on having already achieved MAP goal before asking whether dose stratifies survivors from non-survivors.

---

## 2. EDITORIAL VERDICT

**MAJOR REVISION** (accept-leaning, not reject-leaning).

The finding survives its hardest methodological attacks. The collider test is the make-or-break for the at-target framing, and it passed (interaction p = 0.072, NS). MICE resolves the informative-missingness threat and yields OR 2.04 [1.85, 2.24], stronger than the conservative complete-case estimate. The invasive-MAP sensitivity (OR 3.10, gradient 10.5x) goes in the mechanistically predicted direction. The E-value of 2.5 is modest but not dismissible for an ICU cohort where unmeasured severity confounders (GCS, PaO2/FiO2, shock etiology) are genuine. The at-target conditioning is a real differentiating move relative to VDI and BPRI.

**The single most likely reason a CCM reviewer still rejects:**

The paper presents a single-cohort MIMIC-IV analysis with no external replication, in a space where Shen et al. (Critical Care 2026) already published BPRI trajectory phenotyping on MIMIC-IV plus eICU validation just months earlier. A reviewer who knows that paper will argue: "The authors are doing another MIMIC-IV vasopressor-dose/MAP mortality analysis and calling the at-target conditioning the novel move, but without eICU (or any external data) showing the AUC gap holds in an independent population, this is one conditioning choice in one database." The objection is not fatal — the at-target conditioning genuinely is new — but without external replication the paper's defensibility rests entirely on the framing argument, and a motivated reviewer can sustain a rejection on that basis alone.

---

## 3. THE HONEST ABSTRACT

**Vasopressor Requirement at Achieved MAP Target Stratifies a 9-Fold Mortality Gradient That the Pressure Itself Cannot Detect: A Landmark Cohort Analysis of 7,841 ICU Stays**

### Objective

Among ICU patients receiving vasopressor support, the MAP value is the regulated output of a feedback control system whose effort is the vasopressor dose. Prior work (VIS, VDI, BPRI) has shown that dose-to-MAP ratios predict mortality; none has conditioned the analysis on patients who have already achieved MAP target. We asked whether, within the population that monitoring classifies as hemodynamically managed, the vasopressor requirement carries discriminative mortality information that the MAP value does not.

### Methods

Retrospective landmark cohort from MIMIC-IV (BIDMC, 2008–2019). Inclusion: ICU stays with vasopressor support, median first-24h MAP in [65, 85] mmHg, fewer than 10% of MAP readings below 65 mmHg, and alive at 24 hours (at-target cohort n = 7,841; overall vasopressor cohort n = 23,920). Exposure: first-24h norepinephrine-equivalent load (NEE, mcg/kg/min) as a continuous predictor and in quartiles. Primary outcome: post-24h in-hospital mortality (landmark design, defeating reverse causation). Out-of-fold AUC compared for MAP alone vs. NEE alone within the at-target stratum. Fully adjusted OR estimated by logistic regression with multiple imputation (MICE, m = 10, Rubin's rules) adjusting for age, lactate, creatinine, bilirubin, platelets, and comorbidity burden. Collider bias — an inherent risk of conditioning on a post-treatment node (at-target MAP) — was tested by comparing the fully adjusted NEE–mortality OR across the at-target and not-at-target strata. Pre-specified sensitivity analyses: invasive (arterial-line) MAP only, and comparison of the requirement-vs-MAP AUC gap across strata.

### Results

Within the at-target cohort (mortality 12.4%), first-24h NEE load stratified post-24h mortality monotonically: Q1 3.1%, Q2 7.4%, Q3 11.4%, Q4 27.8% (9-fold range). Fully adjusted MICE-pooled OR per SD of log NEE-load: 2.04 [95% CI 1.85, 2.24]; E-value 2.5 (CI lower bound 2.16). Out-of-fold AUC within the at-target band: requirement 0.743, MAP alone 0.475. The requirement-vs-MAP AUC gap was 0.268 at target vs. 0.156 outside it, a near-doubling as MAP becomes the regulated output. The collider test was non-significant (interaction OR p = 0.072), indicating the association is not a selection artifact of the at-target conditioning. In arterial-line patients (n = 6,301, where MAP is genuinely invasively regulated), the age-adjusted OR was 3.10 [2.82, 3.45] and the mortality gradient spanned 10.5-fold. Unlike VDI (dose/MAP ratio; Miyamoto/BEAT-SHOCK, Shock 2025) and BPRI (MAP/VIS trajectory phenotyping; Shen et al., Critical Care 2026), neither of which restricts analysis to the at-target stratum, this finding is conditioned on MAP goal achievement — the setting where clinicians are most likely to be falsely reassured by the blood pressure reading. Limitation: single-cohort MIMIC-IV; MAP AUC of 0.475 is partly a restriction-of-range artifact; no external replication; observational design with unmeasured severity confounders bounded but not eliminated by the E-value.

### Conclusions

Among ICU patients whose MAP is at target, the vasopressor requirement stratifies a 9-fold mortality gradient (3.1% to 27.8%) that the MAP value itself cannot detect. The requirement-vs-MAP information gap nearly doubles once MAP is at goal. This is a risk-stratification finding with an immediate monitoring implication: vasopressor dose required to maintain target MAP should be recorded and communicated as a prognostic signal even — particularly — when the MAP is normal. External replication and prospective decision-curve evaluation are required before this signal is incorporated into clinical monitoring protocols.

---

## 4. THE ONE ADDITIONAL ANALYSIS THAT MOST RAISES TIER OR DE-RISKS ACCEPTANCE

**eICU-CRD external replication of the within-target AUC gap, with a formal bootstrap confidence interval around the gap statistic (0.268 - 0.156 = 0.112).**

Specifically: apply the identical at-target stratum definition ([65, 85] mmHg, <10% below 65, alive at 24h) to eICU-CRD, compute the requirement-vs-MAP AUC gap within and outside that stratum, and report whether the gap is (a) directionally replicated and (b) the CI of the gap excludes zero. This is realistic: eICU is publicly available, the preprocessing pipeline already exists in the MIMIC implementation, and the sample sizes in eICU (>130,000 unit-stays, a fraction vasopressor-on) are sufficient. The Shen BPRI paper already validated on eICU, which means reviewers will ask why this paper does not.

Why this analysis specifically and not others:
- A formal CI on the AUC gap (currently reported as point estimates 0.156 and 0.268) would convert the gap from an observation to a tested quantity — addressing the quantitative reviewer's natural objection.
- External replication directly answers the single most likely rejection reason (single-cohort MIMIC-IV in a crowded prior-art space).
- Decision-curve analysis or NRI within the normal-MAP group would demonstrate clinical net benefit, which is valuable but secondary: the AUC gap is what establishes the information-theoretic claim that drives the paper's thesis; the DCA would help a revision but would not de-risk the desk-reject.

A manuscript pairing MIMIC-IV discovery + eICU replication of the AUC gap, with a CI on that gap statistic, would meet the standard that Shen et al. 2026 set for the same database and would be substantially harder to reject on prior-art grounds.

---

## 5. SUPPLEMENTARY EDITORIAL NOTE — What the Abstract Must NOT Do

For completeness, the following framings were considered and rejected as either overclaiming or creating a reviewable weakness:

- **Do not lead with "MAP is uninformative."** MAP AUC 0.47 within the target band is partly a restriction-of-range artifact by construction. Lead with the requirement side: AUC 0.74, 9-fold gradient, OR 2.04.
- **Do not claim the control-theory premise closes causal inference.** MAP CV < dose CV is a regulation identity, not an empirical causal discovery. The premise is stated to justify the conditioning stratum, not to establish causality.
- **Do not call this a trait.** ICC 0.07 across encounters (retracted Round 2). This is an acute, within-encounter, outcome-linked signal.
- **Do not omit VDI and BPRI.** A CCM reviewer familiar with BEAT-SHOCK 2025 or Shen Critical Care 2026 will desk-reject a manuscript that fails to name and distinguish those constructs in the Introduction.
- **Do not claim decision benefit.** Concordance analysis and decision curves have not been run in the normal-MAP subgroup. The finding is risk-stratification; clinical actionability requires prospective evaluation.
